| 舒思与维思通治疗精神分裂症的对照研究 |
| |
| 引用本文： | 刘增龙,韩建生,成玉敏,颜敏,周会爽.舒思与维思通治疗精神分裂症的对照研究[J].河北职工医学院学报,2006,23(2):14-15,21. |
| |
| 作者姓名： | 刘增龙 韩建生 成玉敏 颜敏 周会爽 |
| |
| 作者单位： | 河北省第六人民医院,河北,保定,071000 |
| |
| 摘 要： | 目的比较舒思和维思通治疗分裂症的疗效和副作用.方法共纳入符合CCMD-3精神分裂症诊标准的患者60例,随机分为两组,分别予以舒思和维思通治疗8周.采用阳性症状和阴性症状量表(PANSS)评定疗效.不良反应症量表(TESS)评定副作用.结果舒思的总有效率为87%,显效率为66%,无效率为13%.与维思通相比起效慢.第三周才产生疗效.其副作用主要是嗜睡和活动减少.结论舒思是一种安全有效的抗精神病药.
|
| 关 键 词： | 舒思 维思通 精神分裂症 疗效 |
| 文章编号： | 1008-6692（2006）02-0014-03 |
| 收稿时间： | 04 5 2005 12:00AM |
| 修稿时间： | 2005-04-05 |
Study on Quetiapine Fumarate and Risperidone in the treatment of schizophrenia |
| |
| Liu Zenglong, Han Jiansheng, Cheng Yumin ,et. al..Study on Quetiapine Fumarate and Risperidone in the treatment of schizophrenia[J].Journal of Hebei Medical College for Continuing Education,2006,23(2):14-15,21. |
| |
| Authors: | Liu Zenglong Han Jiansheng Cheng Yumin et al |
| |
| Abstract: | Objective To compare the efficacy and side effects of Quetiapine Fumarate and Risperidone in the treatment of schizophrenia.Methods 60 patients with schizophrenia according to CCMD-3 were involved in this study,they were randomly assigned to Quetiapine Fumarate group (n=30) and Rispeidone group (n=30) and treated for 8 weeks.PANSS was adopted to evaluate the efficacy.TESS was adopted to evaluate side effects. Results The overall effective rate,the obvious effective rate and the inefficacy rate of Quetiapine Fumarate were 87%,65% and 13% respectively,but the effect time of Quetiapine Fumarate was at the third week,and lower than that of Risperdone,its side effects were more sleep and less activity.Conclusion Quetiapine Fumarate is an effective and safe antipsychiotic drug. |
| |
| Keywords: | Quetiapine Fumarate Risperdal schizophrenia efficacy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
